$RGPX
REGENEREX PHARMA, INC.

2022 Q2 Form 10-Q Financial Statement

#000147237522000076 Filed on August 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2021 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.071K $497.00
YoY Change 115.49%
% of Gross Profit
Operating Expenses $17.29K $11.69K
YoY Change 47.89%
Operating Profit -$17.29K -$11.69K
YoY Change 47.89%
Interest Expense $15.52K $12.74K
YoY Change 21.79%
% of Operating Profit
Other Income/Expense, Net -$5.919K -$16.99K
YoY Change -65.16%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$23.20K -$33.95K
YoY Change -31.66%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 277.1M shares 127.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q2 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $1.672K $5.954K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $2.500K
Receivables
Other Receivables
Total Short-Term Assets $4.172K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.355K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $4.172K
Total Long-Term Assets $6.355K
Total Assets $10.53K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $57.49K
YoY Change
Accrued Expenses $88.83K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $746.9K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $746.9K
Total Long-Term Liabilities
Total Liabilities $1.019M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$1.958M
YoY Change
Common Stock $277.1K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.009M -$869.0K
YoY Change
Total Liabilities & Shareholders Equity $10.53K
YoY Change

Cashflow Statement

Concept 2022 Q2 2021 Q2
OPERATING ACTIVITIES
Net Income -$23.20K -$33.95K
YoY Change -31.66%
Depreciation, Depletion And Amortization $1.071K $497.00
YoY Change 115.49%
Cash From Operating Activities -$35.07K -$22.49K
YoY Change 55.91%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $34.10K $21.55K
YoY Change 58.27%
NET CHANGE
Cash From Operating Activities -$35.07K -$22.49K
Cash From Investing Activities
Cash From Financing Activities $34.10K $21.55K
Net Change In Cash -$968.00 -$948.00
YoY Change 2.11%
FREE CASH FLOW
Cash From Operating Activities -$35.07K -$22.49K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001357878
CY2022Q2 dei Amendment Flag
AmendmentFlag
false
CY2022Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2022Q2 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2021Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2021Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2022Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2021Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2022Q2 us-gaap Interest Paid
InterestPaid
usd
CY2021Q2 us-gaap Interest Paid
InterestPaid
usd
CY2022Q2 dei Document Type
DocumentType
10-Q
CY2022Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q2 dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2022Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 dei Entity File Number
EntityFileNumber
000-53230
CY2022Q2 dei Entity Registrant Name
EntityRegistrantName
REGENEREX PHARMA, INC.
CY2022Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0535345
CY2022Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
5348 Vegas Drive #177
CY2022Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2022Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2022Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89108
CY2022Q2 dei City Area Code
CityAreaCode
(702)
CY2022Q2 dei Local Phone Number
LocalPhoneNumber
273-3772
CY2022Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q2 dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
277112660 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1672 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2640 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2500 usd
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5256 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
4172 usd
CY2022Q1 us-gaap Assets Current
AssetsCurrent
7896 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
24245 usd
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
23174 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6355 usd
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7426 usd
CY2022Q2 us-gaap Assets
Assets
10527 usd
CY2022Q1 us-gaap Assets
Assets
15322 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
57491 usd
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
63027 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
131787 usd
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
131687 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
221192 usd
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
221192 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
88832 usd
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91667 usd
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
247630 usd
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
152880 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
746932 usd
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
660453 usd
CY2022Q2 us-gaap Notes Payable
NotesPayable
272416 usd
CY2022Q1 us-gaap Notes Payable
NotesPayable
340486 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1019348 usd
CY2022Q1 us-gaap Liabilities
Liabilities
1000939 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
675000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277112600 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
277112600 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277112600 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
277112600 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
277113 usd
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
277113 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
671963 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
671963 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1957897 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1934693 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1008821 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-985617 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10527 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15322 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17285 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11688 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
17285 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
11688 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17285 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11688 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
15518 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
12742 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9599 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4247 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5919 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16989 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-23204 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-28677 usd
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-5275 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-33952 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.00
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
277112660 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127112660 shares
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-33952 usd
CY2021Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-5275 usd
CY2022Q2 us-gaap Depreciation
Depreciation
1071 usd
CY2021Q2 us-gaap Depreciation
Depreciation
497 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9599 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4247 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2756 usd
CY2021Q2 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2064 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6092 usd
CY2021Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8779 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35068 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17218 usd
CY2021Q2 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-5275 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35068 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22493 usd
CY2022Q2 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
100 usd
CY2022Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
34000 usd
CY2021Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
21545 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34100 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21545 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-968 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-948 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2640 usd
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6902 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1672 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5954 usd
CY2022Q2 reg1357878 Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
1435 usd
CY2021Q2 reg1357878 Accrued Interest Converted Into Note Payable To Shareholder
AccruedInterestConvertedIntoNotePayableToShareholder
13451 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-835026 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-33952 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-868978 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-985617 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23204 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1008821 usd
CY2022Q2 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0px; text-align: justify; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.  The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced.  The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months.  The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds.  <span style="font-size: 10pt">These unique products strategically position the Company to enter the wound treatment market in the U.S.</span></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Management has decided to focus on this new business development.  The financial results for periods prior to the abandonment of the previous business line have been reflected in the accompanying statement of operations as discontinued operations as this change represented a strategic shift in our business that had a major effect on our operations and financial results.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations.  No revenue has historically been derived from the assets purchased.  Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The wound care healing space is well suited for Home Care service providers that are funded by the US Government. The majority of manufacturing and distribution will be outsourced. However, strategic planning and development will be performed internally by the Company.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p>
CY2022Q2 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-18
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability
AssetAcquisitionContingentConsiderationLiability
10000000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1957897 usd
CY2022Q2 reg1357878 Current Liabilities In Excess Of Current Assets
CurrentLiabilitiesInExcessOfCurrentAssets
1008821 usd
CY2022Q2 us-gaap Property Plant And Equipment Preproduction Design And Development Costs
PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts
<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Website</i></p> <p style="margin: 0px"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three months ended June 30, 2022 and 2021 was $1,071 and $497, respectively.</p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span class="highlightanchor pagination" id="page_7"/></p>
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1071 usd
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
497 usd
CY2022Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
3283 usd
CY2021Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
3266 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
131787 usd
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
131687 usd
CY2022Q2 us-gaap Debt Instrument Maturity Date Range Start1
DebtInstrumentMaturityDateRangeStart1
2022-07-02
CY2022Q2 us-gaap Debt Instrument Maturity Date Range End1
DebtInstrumentMaturityDateRangeEnd1
2024-06-23
CY2022Q2 us-gaap Accounts Payable Interest Bearing Current And Noncurrent
AccountsPayableInterestBearingCurrentAndNoncurrent
12235 usd
CY2021Q2 us-gaap Accounts Payable Interest Bearing Current And Noncurrent
AccountsPayableInterestBearingCurrentAndNoncurrent
9476 usd
CY2021Q4 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
150000000 shares
CY2021Q4 us-gaap Business Combination Contingent Consideration Arrangements Description
BusinessCombinationContingentConsiderationArrangementsDescription
up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure

Files In Submission

Name View Source Status
0001472375-22-000076-index-headers.html Edgar Link pending
0001472375-22-000076-index.html Edgar Link pending
0001472375-22-000076.txt Edgar Link pending
0001472375-22-000076-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ixform10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
reg1357878-20220630.xsd Edgar Link pending
reg1357878-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
reg1357878-20220630_def.xml Edgar Link unprocessable
ixform10q_htm.xml Edgar Link completed
reg1357878-20220630_lab.xml Edgar Link unprocessable
regenerexlogo.gif Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
reg1357878-20220630_pre.xml Edgar Link unprocessable